ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2020

Circulating Carotenoids and Subsequent Risk of Rheumatoid Arthritis

Yang Hu1, Karen H. Costenbader2, Elizabeth W. Karlson2 and Bing Lu2, 1Brigham and Women's Hospital, Boston, MA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Antioxidants, biomarkers and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Public Health (ACR): Rheumatoid Arthritis Pathogenesis and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: Antioxidant components in food may be biologically relevant to the prevention of rheumatoid arthritis (RA). Evidence from prospective cohort studies regarding the relationship between blood levels of food source antioxidants and risk of RA is limited. The aim of present study was to examine the association between circulating carotenoids and RA risk.    

Methods: We conducted a nested case-control study consisting of 228 incident RA cases and 674 matched controls with prospectively measured plasma carotenoids (α-carotene, β-carotene, β-cryptoxanthin, lycopene and lutein/zeaxanthin) levels in the Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHS II).  Incident RA cases were diagnosed >3 months after blood draw, matched on birth year, race, menopausal status/hormone use, time of day and fasting status, with 3 controls. Smoking, alcohol intake, dietary data, body mass index (BMI) and physical activity were from the questionnaire prior to blood draw. Seropositive RA was defined as positive RF or ACPA by chart review or measurement. Logistic regressions models estimated odds ratios (OR) and 95% confidence intervals (CI) for RA risk associated with each circulating carotenoid.

Results: The median follow-up time from blood draw until RA diagnosis was 8.6 years (0.3 to 19 years). In the multivariable models, no significant associations were found between any plasma carotenoids and risk of all RA, or of seropositive RA. In contrast, we found circulating α-carotene, β-carotene, β-cryptoxanthin and total carotenoids were inversely associated with seronegative RA risk.  Women in the highest quartile of α-carotene were associated with a 52% reduction in seronegative RA risk (OR=0.48; 95% CI, 0.25-0.92). The risk reduction of the highest quartile of β -carotene was 51% (OR=0.49; 95% CI: 0.24-1.00). Circulating β-cryptoxanthin was also associated with the reduced risk of seronegative RA (p trend 0.05). Being in the highest quartile of total plasma carotenoid concentration was associated with a 58% reduced seronegative RA risk (OR=0.42, 95% CI: 0.22-0.81, ptrend 0.03). There was no significant inverse association of lycopene with seronegative RA.

Conclusion: Circulating carotenoid metabolites were associated with a reduced risk of seronegative RA, but not seropositive RA, suggesting different mechanisms for development of these two RA phenotypes. Further studies are needed to confirm our finding.

 

Table. The association between circulating   carotenoids (quartiles) and risk of seropositive and seronegative RA (Odds   ratio and 95% confidence interval)*

Seropositive   RA (n=135)

 

Q1

Q2

Q3

Q4

P trend

Lutein/zeaxanthin

1.00

1.08(0.62,1.89)

1.32(0.76,2.28)

1.36(0.79,2.37)

0.47

β-cryptoxanthin

1.00

0.87(0.51,1.49)

1.00(0.58,1.72)

1.17(0.67,2.03)

0.93

Lycopene

1.00

1.40(0.81,2.42)

1.53(0.90,2.62)

1.20(0.69,2.10)

0.74

α-carotene

1.00

0.96(0.56,1.67)

1.09(0.63,1.88)

1.28(0.74,2.22)

0.82

β-carotene

1.00

1.50(0.87,2.59)

1.10(0.61,1.98)

1.72(0.98,3.03)

0.44

Total carotenoids**

         1.00

1.26(0.72,2.22)

1.67(0.97,2.90)

1.51(0.85,2.69)

0.44

Seronegative   RA (n=93)

Lutein/zeaxanthin

1.00

1.43(0.80,2.57)

0.81(0.42,1.55)

0.64(0.32,1.28)

0.07

β-cryptoxanthin

1.00

0.82(0.46,1.45)

0.52(0.27,0.99)

0.54(0.28,1.05)

0.05

Lycopene

1.00

1.16(0.63,2.12)

0.89(0.47,1.70)

1.01(0.55,1.88)

0.87

α-carotene

1.00

0.50(0.27,0.91)

0.63(0.34,1.14)

0.48(0.25,0.92)

0.07

β-carotene

1.00

0.77(0.42,1.39)

0.87(0.48,1.58)

0.49(0.24,1.00)

0.07

Total carotenoids**

         1.00

0.37(0.20,0.71)

0.62(0.35,1.11)

0.42(0.22,0.81)

0.03

* Total carotenoids were the sum of   lutein/zeaxanthin, β-cryptoxanthin, total lycopene, α-carotene and   β-carotene.

** Adjusting for matching factors (age, menopausal status,   postmenopausal hormone use, and day, time, and fasting status at the time of collection),   smoking status (never, past, current) and body   mass index. Additional adjustment for alcohol consumption, healthy eating   index, physical activity and total calories intake did not change the   results.


Disclosure:

Y. Hu,
None;

K. H. Costenbader,
None;

E. W. Karlson,
None;

B. Lu,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/circulating-carotenoids-and-subsequent-risk-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology